Amphastar Pharmaceuticals Inc (AMPH) 시세

I've bought some AMPH at $31. Great products and decent numbers. Hoping for a move back up to the low $40's.

AMPH buy 42.3299

https://finance.yahoo.com/quote/AMPH/profile?p=AMPH

https://www.barchart.com/stocks/quotes/AMPH

https://finviz.com/quote.ashx?t=AMPH

https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=AMPH

https://stockcharts.com/c-sc/sc?chart=AMPH,uu[e,a]dhclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b

https://www.barchart.com/etfs-funds/quotes/AMPH/technical-chart?plot=CANDLE&volume=toAMPH&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=TREND&sym=AMPH&grid=1&height=500&studyheight=100&timeframe=2%20Months




normal chart









log chart









normal chart








log chart

AMPH 50/200sma crossed here...Nice bullish sign.

fda approval

Gearing up for another amazing surprise quarter of positive earnings!!! Always a nice push down just before the after earnings report POP!

reading my friend, their drug helper going on shelf item, any thoughts ?????

China has several generic-insulin products already on the market.

Do you see them investing in China to develop generic insulin since China has a huge diabetes problem?

Squeezing up! I love it

Momenta, Sandoz allowed to broaden claims over quality test patent

A federal judge has allowed Momenta Pharmaceuticals and Sandoz Inc to broaden a lawsuit accusing Amphastar Pharmaceuticals of infringing a patent on quality control methods used in making the blood thinner enoxaparin, the generic form of French drug maker Sanofi's Lovenox.

U.S. District Judge Nathaniel Gorton in Massachusetts said Tuesday that Momenta and Sandoz could add new infringement allegations to their complaint in light of a ruling last November by the U.S. Court of Appeals for the Federal Circuit that California-based Amphastar is not protected by a safe harbor provision in the patent law.

http://www.reuters.com/article/health-patent-idUSL1N19F0C7

Ampha market cap is about 750 M and is valued way less than the damage they caused. Momenta was making about a 1 M a day on lovonox before the Ampha debacle. bp

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123595244

AMPH is not a start-up, but it has trouble making money, evidently. The past 3 quarters have basically been at break-even.

Update on Lovenox patent case: #msg-113632332.

No issue.

IT IS 32 MILLION FROM NOW TO END OF 2015
IT IS THE 2ND TO LAST QUESTION

will not respond again.

http://www.amphastar.com/

They did give a number for their MANNKIND production only that it was very profitable. Your wrong. Sorry. You need to listen again.

You just did not hear it ....
call AMPH and you will find out they did.
If I owned stock I would call ....

They did not give any dollar figure for their sales to MannKind.

This EPS info is wrong.
Sorry ....

Phaeton
Did you catch only 32 million sales to MNKD in 2015
in the conf call ?

Share buyback program for AMPH

On November 6, 2014, the Company's Board of Directors authorized a $10.0 million share buyback program, which is expected to continue for an indefinite period. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.

Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company's management and in accordance with the requirements of the Securities and Exchange Commission.

Do you have a phone number for that call you posted ?

Phaeton
Is that what you are going to do ?

Dump all you mannkind and buy amph.

AMPH NOV 28, 2014

Amphastar Pharmaceuticals, Inc. (AMPH) is a specialty pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AMPH’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Amphastar Pharmaceuticals could be a solid choice for investors.Current Quarter Estimates for AMPH In the past 30 days, 1 estimate has gone higher for Amphastar Pharmaceuticals while none has gone lower in the same time period. The trend has been pretty favorable too, with loss estimates narrowing down from 11 cents a share 30 days ago, to 6 cents today, a move of over 45.5%.Current Year Estimates for AMPH Meanwhile, Amphastar Pharmaceuticals’ current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to 1 moving lower. The loss estimate trend has also seen a boost for this time frame, narrowing down from 16 cents per share 30 days ago to 14 cents per share today, an improvement of 12.5%.Bottom Line The stock has also started to move higher lately, adding 6.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.

AMPH 30 This chart has gotten a little ahead of it self . IMHO

AMPH M

AMPH D

I went back and listened to the Amphstar call again. They said that they had 9 billion in the pipeline on generic products using their inhalation side of their business. They particularly stated that they were working on PARTICULE ENGINEERING of complex molecules. They view their inhalation side of the business with a higher value. That Amphstar would do the science side and that a Pharm partner would do the sales and marketing side. Makes me wonder if they are going to use the Technosphere on some generic drugs. I would encourage you go listen to the call and give your opinion. I found the call interesting. this part was in the last 7 or 8 mins of the call. One of the generics mentioned was Advir

Piper Jaffery call this morning.

Amphstar said on their call today, That they became instantly profitable based on the deal they made to supply insulin to mannKind. I missed part of the call so I don't know if they talked earlier about that purchased by mankind but I thought it was good that it was mentioned about their profitability was based on their contract and future sales to MannKind. They also stated that they had some new drugs in their pipeline where they would be partnering with another firm. Did not mention Mannkind but the decussion was on particle molucules and peptides involving inhalation drugs. I thought it was a very interesting call. I will try and go back and listen to the 5 mins that I missed when the call is reposted.

I'm interested due to their naloxone product- I can't figure out what was with that mid-day spike today but I'm trying to get a feeling for this one

I do a little.

Anyone been following this company?

Go check out the Friends of MannKind board on this site.
If you want information on the partner to AMPH. Or post information regarding MNKD partnership with MNKD here on this board.

Home > Boards > Free Zone > User's Groups >
Friends of MannKInd

Forbes on Fox just recommended buying AMPH. Funny how people like the supplier of insulin enough but not the producer of Afrezza.

good posting on AMPHASTAR partner.
Moved from the MNKD Board.

Ha Ha Ha we are trying to be a POS penny stock like the ones you follow. Perhaps our bad Karma will get us to that position. But I am betting that won't happen. Perhaps today its ugly but let's see where we are this time next year.

A good Doctor had these comments on another message board. Perhaps he see's the future of Diabetic treatment.

Let me give you the perspective of a primary care physician. Sanofi tried for a long time to push Apidra to us. There was not enough of a difference between it and our standards, Novolog and Humalog, to convince many to change, so the sales with primary care docs fell flat. As a result Sanofi now positions Apidra as the preferred insulin for pumps and they have been somewhat successful with that marketing strategy. Afrezza on the other hand is a totally different product. It is inhaled, not just another shot. And it does not come with a complicated delivery device like Exubera did. Have you ever seen the delivery device for Exubera? It was extremely complicated. Despite being instructed in its use on several occasions I could see that it was far too complicated for the average patient and therefore never prescribed Exubera. The Dreamboat on the other hand is extremely simple and requires less instruction time than even the simplest of the insulin pens. And yes, I have actually had a Dreamboat in my hands so I know what I am talking about. This will save me time in my office, something that is going away quickly as the practice of medicine becomes more and more complex thanks to all the regulations from Uncle Sam and the other insurance companies. The reason that Exubera failed was the delivery device first of all and the fact that it was in milligrams, not units (and the mg to unit conversion was not even 1:1, too complicated). All a patient has to do with the Dreamboat is open it up, insert a cartridge, close it, and breathe in deeply. And every 2 weeks just drop the used Dreamboat in a trash can and pull out a fresh clean Dreamboat. No cleaning, no replacing parts, etc, etc, etc that were required with the Exubera bong. And it will fit in the pocket of any man, something that a man could actually do with the Exubera device but resulted in him getting all sorts of crude comments from those around him.
For those of you who think for whatever reason that Afrezza will fail you should think again. I have been doing this a long, long time. This is going to be a game changer. In diabetes for now. But in many medical fields in the coming years. I am not pumping as you call it on this board, I am simply looking at what goes on in an average primary care practice. I am sure that there will be criticisms of this post. That seems to occur for most posts that look at the good side of Afrezza. Bring it on. And mark my word. And mark this post. (Last 2 sentences thrown in on purpose to raise the hair on the back of the necks of those who get all upset when they read those words.)

I look forward to my investment returning me a a great increase in PPS and the game changer it brings to the Diabetic community. So if MannKind is not at $15.00 this time next year its a failure. If the company is not purchased by SNY for $30.00 per share next year its a failure. But at least I have enjoyed the fact that long term this product will benefit Millions of diabetics in the USA and the world. Mark my word.

Mannkind is not a plane crash.

Yep be we will be rising soon on MNKD. Should have bought this at 9.00 instead of buying more of MannKind. But I bet we all will be ok. In DC wed - Sunday. Up for coffee in sat or Sunday

Silent riser I love it!

Only what is know publicly. MannKind will be buying a lot of insulin which will be sold by Sanofi.

Can you go into more detail about the "Mannkind contract" that you mentioned?

Should have reseved some extra cash for AMPH. Seems to be moving in the right direction. You have to think that most of it is because of the MannKind contract.

Definitely a good stock to keep an eye on With it's ties to mannkind this will be a winner

$AMPH DD Notes ~ http://www.ddnotesmaker.com/AMPH

bullish

$AMPH recent news/filings

## source: finance.yahoo.com

Tue, 26 Aug 2014 10:55:03 GMT ~ Increased Earnings Estimates Seen for Amphaster Pharmaceuticals (AMPH): Can It Move Higher?


read full: http://finance.yahoo.com/news/increased-earnings-estimates-seen-amphaster-105503341.html
*********************************************************

Mon, 25 Aug 2014 10:37:10 GMT ~ Why Amphastar Pharmaceuticals (AMPH) Stock Might be a Great Pick


read full: http://finance.yahoo.com/news/why-amphastar-pharmaceuticals-amph-stock-103710002.html
*********************************************************

Wed, 13 Aug 2014 20:17:38 GMT ~ AMPHASTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/140813/amph10-q.html
*********************************************************

Tue, 12 Aug 2014 20:17:56 GMT ~ Amphastar Pharmaceuticals Reports Revenues of $49.0 Million for the Second Quarter Ended June 30, 2014

[at noodls] - Previous Release RANCHO CUCAMONGA, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) ("Amphastar" or the "Company") today reported results for ...

read full: http://www.noodls.com/view/95D663AB3AE09C53FF0E0DB8C7D9D337DA11E846
*********************************************************

Tue, 12 Aug 2014 20:02:10 GMT ~ AMPHASTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen


read full: http://biz.yahoo.com/e/140812/amph8-k.html
*********************************************************


$AMPH charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$AMPH company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/AMPH/company-info
Ticker: $AMPH
OTC Market Place: Not Available
CIK code: not found
Company name: Amphastar Pharmaceuticals, Inc.
Incorporated In: USA


$AMPH share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$AMPH extra dd links

Company name: Amphastar Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AMPH+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AMPH+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AMPH+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/news - http://finance.yahoo.com/q/h?s=AMPH+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AMPH/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AMPH+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AMPH
DTCC (dtcc.com): http://search2.dtcc.com/?q=Amphastar+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Amphastar+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Amphastar+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AMPH
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AMPH&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AMPH
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AMPH+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AMPH+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AMPH
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AMPH
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AMPH+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AMPH/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AMPH+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AMPH.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AMPH
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AMPH/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AMPH/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AMPH
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AMPH
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AMPH:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AMPH
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AMPH



$AMPH DD Notes ~ http://www.ddnotesmaker.com/AMPH

Five directors recently made small open-market purchases: #msg-105505991.

With SNY and MNKD news, this should bring AMPH up as well I assume.

Don't be crashing my F-15.

We need to be flying high

There is some interesting developments here as for sure

Were you able to read the info?

Can't pull up info without a membership

http://www.sec.gov/edgar/searchedgar/ctorders.htm#.U-ZxTWK9KSN

http://secfilings.nasdaq.com/filingFrameset.asp?CoName=AMPHASTAR+PHARMACEUTICALS%2C+INC%2E&eHTML=&FileName=9999999997%2D14%2D011414%2Etxt&FilePath=%5C2014%5C06%5C25%5C&FormType=CT+ORDER&Market=&RcvdDate=6%2F25%2F2014&site=&sitesubtype=&Ticker=&View=html

Don't see how one could go wrong with this.......
Chart looks good also...